Concert Pharmaceuticals Inc (CNCE) - Financial and Strategic SWOT Analysis Review [Report Updated: 14-03-2018]

Introduction

Concert Pharmaceuticals Inc (CNCE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.

- Corporate strategy – Analyst’s summarization of the company’s business strategy.

- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.

- Company history – Progression of key events associated with the company.

- Major products and services – A list of major products, services and brands of the company.

- Key competitors – A list of key competitors to the company.

- Key employees – A list of the key executives of the company.

- Executive biographies – A brief summary of the executives’ employment history.

- Key operational heads – A list of personnel heading key departments/functions.

- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities – A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Concert Pharmaceuticals Inc (Concert Pharmaceuticals) is a clinical stage biotechnology company which discovers and develops small molecule drugs. The company develops its products using its deuterated chemical entity (DCE) platform to develop novel therapeutics for autoimmune and inflammatory diseases, pulmonary diseases, and disorders of central nervous system (CNS). Its product pipeline includes CTP-543 (deuterated ruxolitinib) for alopecia areata; AVP-786 (deuterated dextromethorphan) indicated for alzheimer’s agitation, major depressive disorder and residual schizophrenia; CTP-730 (deuterated apremilast) for inflammatory diseases; CTP-692, a selective DCE modified analog of the endogenous amino acid, D-serine for Schizophrenia, and JZP-386 (deuterated sodium-oxybate) for narcolepsy. It employs its deuterated compounds to reduce the extent of metabolism in the wall of the intestines and in the liver. Concert Pharmaceuticals is headquartered in Lexington, Massachusetts, the US.

Concert Pharmaceuticals Inc Key Recent Developments

Mar 01,2018: Concert Pharmaceuticals Reports Year Ended 2017 Financial Results

Jan 12,2018: Concert Pharmaceuticals Announces Patent Trial and Appeal Board Did Not Institute PGR Proceeding

Dec 18,2017: Concert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial Officer

Dec 13,2017: Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index

Nov 09,2017: Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents
for Concert Pharmaceuticals Inc (CNCE) - Financial and Strategic SWOT Analysis Review [Report Updated: 14-03-2018]

• Table of Contents

  Table of Contents 3

  List of Tables 5

  List of Figures 5

  Section 1 - About the Company 6

  Concert Pharmaceuticals Inc - Key Facts 6

  Concert Pharmaceuticals Inc - Key Employees 7

  Concert Pharmaceuticals Inc - Key Employee Biographies 8

  Concert Pharmaceuticals Inc - Major Products and Services 9

  Concert Pharmaceuticals Inc - History 10

  Concert Pharmaceuticals Inc - Company Statement 12

  Concert Pharmaceuticals Inc - Locations And Subsidiaries 15

  Head Office 15

  Other Locations & Subsidiaries 15

  Section 2 – Company Analysis 16

  Company Overview 16

  Concert Pharmaceuticals Inc - Business Description 16

  R&D Overview 16

  Concert Pharmaceuticals Inc - Corporate Strategy 18

  Concert Pharmaceuticals Inc - SWOT Analysis 19

  SWOT Analysis - Overview 19

  Concert Pharmaceuticals Inc - Strengths 19

  Concert Pharmaceuticals Inc - Weaknesses 20

  Concert Pharmaceuticals Inc - Opportunities 21

  Concert Pharmaceuticals Inc - Threats 22

  Concert Pharmaceuticals Inc - Key Competitors 23

  Section 3 – Company Financial Ratios 24

  Financial Ratios - Capital Market Ratios 24

  Financial Ratios - Annual Ratios 25

  Performance Chart 28

  Financial Performance 28

  Financial Ratios - Interim Ratios 29

  Financial Ratios - Ratio Charts 30

  Section 4 – Company’s Lifesciences Financial Deals and Alliances 31

  Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

  Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32

  Concert Pharmaceuticals Inc, Recent Deals Summary 33

  Section 5 – Company’s Recent Developments 34

  Mar 01, 2018: Concert Pharmaceuticals Reports Year Ended 2017 Financial Results 34

  Jan 12, 2018: Concert Pharmaceuticals Announces Patent Trial and Appeal Board Did Not Institute PGR Proceeding 35

  Dec 18, 2017: Concert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial Officer 36

  Dec 13, 2017: Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index 37

  Nov 09, 2017: Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update 38

  Aug 08, 2017: Concert Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Company Update 39

  May 30, 2017: Concert Pharmaceuticals Announces Departure of Chief Financial Officer, Ryan Daws 41

  May 02, 2017: Concert Pharmaceuticals Reports First Quarter 2017 Financial Results 42

  Mar 06, 2017: Concert Pharmaceuticals Reports Year Ended 2016 Financial Results 43

  Section 6 – Appendix 45

  Methodology 45

  Ratio Definitions 45

  About GlobalData 49

  Contact Us 49

  Disclaimer 49

List Of Tables
in Concert Pharmaceuticals Inc (CNCE) - Financial and Strategic SWOT Analysis Review [Report Updated: 14-03-2018]

List of Tables

Concert Pharmaceuticals Inc, Key Facts 6

Concert Pharmaceuticals Inc, Key Employees 7

Concert Pharmaceuticals Inc, Key Employee Biographies 8

Concert Pharmaceuticals Inc, Major Products and Services 9

Concert Pharmaceuticals Inc, History 10

Concert Pharmaceuticals Inc, Subsidiaries 15

Concert Pharmaceuticals Inc, Key Competitors 23

Concert Pharmaceuticals Inc, Ratios based on current share price 24

Concert Pharmaceuticals Inc, Annual Ratios 25

Concert Pharmaceuticals Inc, Annual Ratios (Cont...1) 26

Concert Pharmaceuticals Inc, Annual Ratios (Cont...2) 27

Concert Pharmaceuticals Inc, Interim Ratios 29

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32

Concert Pharmaceuticals Inc, Recent Deals Summary 33

Currency Codes 45

Capital Market Ratios 45

Equity Ratios 46

Profitability Ratios 46

Cost Ratios 47

Liquidity Ratios 47

Leverage Ratios 48

Efficiency Ratios 48

List Of Figures, Charts and Diagrams
in Concert Pharmaceuticals Inc (CNCE) - Financial and Strategic SWOT Analysis Review [Report Updated: 14-03-2018]

List of Figures

Concert Pharmaceuticals Inc, Performance Chart (2013 - 2017) 28

Concert Pharmaceuticals Inc, Ratio Charts 30

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 32

Additional Details

Publisher

Global Data

Publisher Information

Reference

203374 | GDPH137836FSA

Number of Pages

49

Report Format

PDF

Related Reports